Gwella

Gwella Goes International with Stronger Microdose Gummies in 2022

Consumer Product of the Year Winner Announces Global Extra-Strength Option for Microdosing


In mid-October 2022, Gwella, a direct-to-consumer functional mushroom brand, is excited to announce the launch of its newest mushroom gummy. Mojo Microdose Gummies – Mojo Macro is an extra-strength version of the brand’s already popular regular-strength Mojo gummies. Gwella’s Mojo gummies offer a legal option for people to experience the benefits of microdosing: focus, energy, mental clarity, and feelings of positivity.

Growing Popularity

Touted as the world’s first legal microdose alternative, Gwella’s non-hallucinogenic gummies, Mojo Microdose gummies, quickly sold out during their 2021 release. In addition to receiving some excellent consumer reviews, Mojo also won Consumer Product of the Year during the 1st Annual Microdose Awards.

After a successful initial run, Gwella ramped up the production of its flagship product to meet a growing consumer base. In response to widespread international interest, the regular- and extra-strength Mojo gummies can now be shipped to customers worldwide, including the UK where consumer demand has been extremely high. Aside from a few countries with stricter restrictions on functional mushrooms, Mojo products are 100% legal.

Functional Ingredients

Mojo gummies are engineered with a stack of unique bioactives to stimulate the reported pharmacological benefits of microdosing psilocybin, without any of the legal worries.

Mojo uses proprietary Cordyceps that helps naturally boost mood, while the nootropics combined with Lion’s Mane help enhance focus and improve mental clarity. After taking Mojo gummies regularly, some users can decrease their daily caffeine intake without affecting their energy levels. The addition of ginseng and slow-releasing caffeine provide a non-jittery brain boost and a reduction in brain fog.

Microdosing magic mushrooms allow people to feel creative, clear-headed, and present. Gwella’s Mojo gummies help people explore the psychedelic world without the illegal components. According to Daniel Sanders, Gwella’s Chief Science Officer, Mojo’s “non-hallucinogenic, non-psychedelic formula leverages the adaptogenic and functional benefits of mushrooms to improve individual baselines across their health and productivity.”

The synergy of the active ingredients working together make the Mojo formula both safe and effective.

Short and Long-Term Benefits

As health and wellness continue to trend in a post-pandemic world, Mojo gummies serve as a legal microdose alternative that affords immediate and long-term wellness advantages. Gwella recommends taking no more than six gummies in a 12-hour period and alternating five days on and two days off if you plan on starting a routine.

In as little as a half-hour, users can experience a clean and consistent energy boost that mimics the flow state associated with microdosing for 5+ hours! For some, taking one Mojo gummy can increase focus, mental clarity, and calmness after the release period. Others may need to take more than one to experience their next level focus.

Long-term benefits, like improved mood and brain cognition, can occur when you take the gummies as part of a routine. Although Gwella doesn’t make medical claims since they haven’t conducted clinical trials yet, consumers have reported that taking Mojo gummies helps them get a midday pick-me-up, achieve better sleep and generally attain an improved mental state.

The Conversation (0)

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

  • Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025
  • COMP006 data will now be announced after 26-week time point, expected in the second half of 2026
  • Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30%
  • Cash position of $207 million
  • Conference call October 31 at 8:00 am ET (12:00 pm UK)

Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less

Seelos Announces Second Postponement of its Annual Meeting of Stockholders

Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024 from its originally scheduled date of Friday, September 27, 2024 has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.comSEEL2024 on Monday, November 25, 2024 at 8:00 a.m., Eastern Time . The record date for the Annual Meeting, August 19, 2024 is unchanged and applies to the postponed Annual Meeting.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024.

The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×